US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ARIA Opportunities ETF

25.17

+0.34981.41%

Post-market: 24.82-0.3498-1.39%16:10 EDT

Volume:12

Turnover:332

Market Cap:12.16M

PE:- -

High:25.17

Open:24.82

Low:25.17

Close:24.82

52wk High:26.03

52wk Low:24.76

Shares:483.20K

Float Shares:483.20K

Volume Ratio:0.83

T/O Rate:0.00%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Company Profile

Company Name:

ARIA Opportunities ETF

Exchange:

ARCA

Establishment Date:

- -

Employees:

- -

Office Location:

10900 Hefner Pointe Drive,Suite 400,Oklahoma City,Oklahoma,United States

Website:

http://www.ariad.com

Zip Code:

73120

Phone:

Fax:

405-896-5825

Introduction:

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/ARIA/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ARIA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARIA\",,,,,undefined,":{"symbol":"ARIA","market":"US","secType":"STK","nameCN":"ARIA Opportunities ETF","latestPrice":25.1689,"timestamp":1787342400000,"preClose":24.8191,"halted":0,"volume":12,"hourTrading":{"tag":"盘后","latestPrice":24.8191,"preClose":25.1689,"latestTime":"16:10 EDT","volume":4,"amount":100.6756,"timestamp":1787343003875,"change":-0.3498,"changeRate":-0.013898,"amplitude":0},"delay":0,"changeRate":0.014093984068721343,"floatShares":483200,"shares":483200,"eps":0,"marketStatus":"Market Closed","change":0.3498,"latestTime":"08-21 16:00:00 EDT","open":24.8191,"high":25.1689,"low":25.1689,"amount":332,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":24.8191,"nav":25.19,"aum":12171478.81,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":24.8191,"preClose":25.1689,"latestTime":"16:10 EDT","volume":4,"amount":100.6756,"timestamp":1787343003875,"change":-0.3498,"changeRate":-0.013898,"amplitude":0},"volumeRatio":0.8333350694480613},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARIA\",,,,,undefined,":{"symbol":"ARIA","floatShares":483200,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.8333350694480613,"shares":483200,"dividePrice":0,"high":25.1689,"amplitude":0,"preClose":24.8191,"low":25.1689,"week52Low":24.76,"pbRate":"--","week52High":26.0317,"institutionHeld":0.5771,"latestPrice":25.1689,"eps":0,"divideRate":0,"volume":12,"delay":0,"ttmEps":0,"open":24.8191,"prevYearClose":24.76,"prevWeekClose":25.7833,"prevMonthClose":24.76,"prevQuarterClose":24.76,"fiveDayClose":25.7833},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ARIA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ARIA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ARIA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1992791129,"address":"10900 Hefner Pointe Drive,Suite 400,Oklahoma City,Oklahoma,United States","zipCode":"73120","officePhone":"405-778-8377","officeFax":"405-896-5825"},"stockCompanyDetail":{"websiteUrl":"http://www.ariad.com","stockEarnings":[{"period":"1week","weight":-0.0238},{"period":"1month","weight":0.0165},{"period":"ytd","weight":0.0165}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":0.0245},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.1107},{"period":"1year","weight":0.2048},{"period":"ytd","weight":0.1229}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.","exchange":"ARCA","name":"ARIA Opportunities ETF","nameEN":"ARIA Opportunities ETF"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"ARIA\",market:\"US\",,,undefined,":null}}